ClinicalTrials.gg
RecruitingNCT07589062HEAL-MSUpdated Nov 16, 2026

Healthy Eating and Active Living for People Living With Multiple Sclerosis (HEAL MS): A Lifestyle Program for People With Multiple Sclerosis

An interventional study of Multi-Domain Lifestyle Intervention in Multiple Sclerosis (MS) - Relapsing-remitting and Multiple Sclerosis, sponsored by New York University Abu Dhabi. Recruiting at 1 site in United Arab Emirates. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by New York University Abu Dhabi · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Nov 16, 2026Now RecruitingSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn whether a structured lifestyle program can improve health and wellbeing in people living with multiple sclerosis (MS). The program focuses on four areas: nutrition, physical activity, sleep, and stress management. The study will also examine how lifestyle changes affect biological markers related to inflammation, metabolism, and immune function.

The main questions the study aims to answer are:

Can a 12-week lifestyle program improve fatigue, physical function, sleep, and quality of life in people with MS? Do lifestyle changes influence biological markers related to inflammation, metabolism, and mitochondrial function?

Participants will first complete a 12-week observation period to measure their usual lifestyle and health. After this, they will take part in the 12-week HEAL MS lifestyle program.

Participants will:

Attend four assessment visits at Yas Clinic (baseline, before the intervention, after the intervention, and three months later) Participate in two supervised online exercise sessions per week during the 12-week program Follow a structured nutrition plan, with meals provided during the first two weeks Use a mobile application to log daily habits related to exercise, nutrition, sleep, and stress Complete questionnaires and physical tests and provide blood, saliva, and stool samples during assessment visits

Researchers will analyze these data to understand whether lifestyle interventions can support symptom management and overall health in people living with MS.

Read the detailed description

Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system characterized by neurodegeneration, demyelination, and progressive disability. Although current treatments primarily focus on immune suppression, growing evidence indicates that non-immune mechanisms, including mitochondrial dysfunction, metabolic imbalance, and chronic systemic inflammation, play a significant role in disease progression and symptom burden. Multi-omics studies have identified disruptions in mitochondrial proteins, lipid and amino acid metabolism, and inflammatory signaling pathways in individuals with MS, suggesting that systemic metabolic processes contribute to disease activity and may represent modifiable therapeutic targets.

HEAL MS (Healthy Eating and Active Living for Multiple Sclerosis) was developed to address these upstream biological drivers through a structured lifestyle intervention integrating nutrition, physical activity, sleep optimization, and stress regulation. The program is culturally adapted for the UAE population and delivered through a hybrid model combining in-person onboarding and digital support via a bilingual (Arabic-English) mobile application that facilitates behavioral tracking, education, and participant engagement.

This study is a 24-month pilot interventional study designed to evaluate the feasibility, acceptability, and biological impact of the HEAL MS program in individuals with relapsing-remitting or progressive MS. Thirty participants will be recruited from collaborating MS clinics. The study uses a within-subject design consisting of a 12-week observation (control) period followed by a 12-week lifestyle intervention. Assessments are conducted at four timepoints: baseline, pre-intervention, post-intervention, and three months after completion of the intervention. This design allows each participant to serve as their own control, improving statistical sensitivity and reducing inter-individual variability.

The intervention targets four behavioral domains. Adaptive movement training consists of supervised small-group sessions conducted twice weekly using functional resistance exercises based on bodyweight, resistance bands, and suspension training. Exercises are designed to improve strength, neuromuscular coordination, and mitochondrial resilience while remaining scalable to accommodate MS-related fatigue and mobility limitations. The nutrition component emphasizes anti-inflammatory, nutrient-dense whole foods with a macronutrient distribution of approximately 40% carbohydrates, 30% protein, and 30% fat. Personalized calorie targets are calculated using the Mifflin-St Jeor equation, and participants receive meal delivery during the initial two weeks to facilitate adherence before transitioning to guided self-preparation. Sleep optimization focuses on circadian-aligned behavioral strategies such as consistent sleep schedules, screen-light reduction, and timing of meals and exercise. Stress regulation includes daily breath-based practices, mindfulness exercises, and vagal nerve-stimulating techniques designed to support autonomic balance. Participant engagement and adherence are supported through daily behavioral tracking using the mobile application.

The study integrates biological, clinical, and behavioral outcomes to evaluate the mechanistic impact of the intervention. Blood samples collected at each assessment will undergo routine clinical chemistry testing and high-resolution molecular profiling. Proteomic analysis will be performed using the Olink Reveal platform, enabling multiplex quantification of over 1,000 plasma proteins related to immune signaling, inflammation, oxidative stress, and metabolic regulation. Metabolomic profiling will be conducted using nuclear magnetic resonance spectroscopy to quantify approximately 250 circulating metabolic biomarkers related to mitochondrial function and systemic metabolism.

Additional outcome measures include body composition assessment using multi-frequency bioelectrical impedance analysis, validated functional performance tests (6-minute step test, five-times-sit-to-stand test, and grip strength), and psychometric instruments assessing fatigue, mood, sleep quality, cognitive performance, and quality of life. Wearable monitoring devices will be used to capture sleep duration, activity levels, and heart rate variability as indicators of physiological recovery and autonomic regulation.

By integrating behavioral intervention with high-resolution molecular profiling, HEAL MS aims to generate mechanistic insight into how lifestyle modification influences metabolic, inflammatory, and mitochondrial pathways in MS. Findings from this pilot study will inform the feasibility and design of larger randomized trials investigating lifestyle-based strategies as complementary approaches to disease management.

02

Conditions studied

  • Multiple Sclerosis (MS) - Relapsing-remitting
  • Multiple Sclerosis

Keywords

  • Multiple Sclerosis
  • Lifestyle Medicine
  • Exercise Intervention
  • Lifestyle Intervention
  • Anti-Inflammatory Diet
  • Multiomics
  • Proteomics
  • Metabolomics
  • Mitochondrial Dysfunction
  • Digital Health
  • Behavioral Change
  • Fatigue
  • Neuroinflammation
  • Lifestyle Diet
03

In context

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

This study's planned enrollment of 30 is below the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Lead sponsor

New York University Abu Dhabi is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed MS diagnosis (McDonald criteria)
  • EDSS score ≤ 6.5 (i.e., ambulatory with or without assistance)
  • Stable disease-modifying therapy for ≥ 3 months
  • Age 18-50
  • Proficiency in English or Arabic
  • Clearance to participate in a structured exercise program
  • Ability to walk, sit and stand independently, and perform light-to-moderate movement patterns, even with modifications
  • Ability and digital literacy to interact with the bilingual HEAL MS mobile app and
  • Access to a computer for participation in online sessions

Exclusion criteria

Exclusion Criteria:

  • Significant cognitive impairment affecting app use and comprehension of the intervention
  • MS relapse within the past 3 months
  • Pregnancy or planned pregnancy
  • Unmanaged psychiatric disorders
  • Other immune-related or chronic inflammatory or metabolic diseases
  • Concurrent enrollment in another lifestyle intervention
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    HEAL MS Lifestyle Intervention

    Participants first complete a 12-week observation period during which they maintain their usual lifestyle. This is followed by a 12-week HEAL MS lifestyle intervention targeting four domains: adaptive movement, anti-inflammatory nutrition, sleep optimization, and stress regulation. The movement component includes twice-weekly supervised online group exercise sessions using scalable functional exercises. The nutrition component provides personalized meal plans with two weeks of meal delivery to support adherence. Sleep and stress modules include circadian hygiene strategies, breathwork, and mindfulness practices. Participants track daily behaviors, wellbeing, and optional wearable data through a bilingual mobile application. Assessments including blood sampling, body composition, functional fitness testing, and questionnaires are conducted at baseline, pre-intervention, post-intervention, and three months post-intervention.

    Other: Multi-Domain Lifestyle Intervention

Interventions

  • OtherMulti-Domain Lifestyle Intervention

    The intervention is a 12-week multi-domain lifestyle program. It targets four behavioral domains: physical activity, nutrition, sleep, and stress regulation. Participants attend twice-weekly supervised online exercise sessions using scalable functional movements performed with bodyweight, resistance bands, and suspension training. The nutrition component provides individualized meal plans based on maintenance calories, emphasizing anti-inflammatory, whole-food nutrition with a macronutrient distribution of approximately 40% carbohydrates, 30% protein, and 30% fat. During the first two weeks, meals are delivered to support adherence. Sleep optimization focuses on circadian-aligned behaviors such as consistent sleep timing and reduced evening light exposure. Stress regulation includes daily breathing exercises, mindfulness practices, and vagal nerve-stimulating techniques. Participants track dadaily behaviors, wellbeing, and wearable data using a billiungual mobile app.

06

What researchers measure

Primary outcomes

  1. Recruitment Rate (Number of Participants Enrolled per Month)

    Number of eligible participants enrolled into the study per month, calculated from the number of participants who consent and complete baseline assessment.

    Time frame: From study start (Month 0) to completion of recruitment (approximately Month 12)

  2. Retention Rate (Percentage of Participants Completing All Study Assessments)

    Percentage of enrolled participants who complete all four assessment timepoints (baseline, pre-intervention, post-intervention, and 3-month follow-up).

    Time frame: Baseline to 36 weeks (end of follow-up)

  3. Exercise Adherence (Percentage of Completed Scheduled Exercise Sessions)

    Proportion of prescribed exercise sessions attended (twice-weekly supervised sessions) during the 12-week intervention period.

    Time frame: Weeks 13-24 (12-week intervention period)

  4. Mobile Application Engagement (Average Daily Completion Rate of App-Based Logs)

    Average proportion of days participants complete daily logs (including energy, fatigue, mood, sleep, and adherence tracking) via the HEAL MS mobile application.

    Time frame: Weeks 13-24 (12-week intervention period)

  5. Acceptability of HEAL MS Intervention (Participant Satisfaction Score)

    Participant-reported satisfaction with the intervention, assessed using a standardized post-intervention questionnaire (e.g., Likert scale rating of overall experience, usability, and perceived benefit).

    Time frame: Week 24 (post-intervention assessment)

Secondary outcomes

  1. Change in Plasma C-Reactive Protein (CRP) Concentration (mg/L)

    CRP will be measured using standard clinical blood chemistry assays. Mean change in CRP concentration will be calculated across timepoints to assess systemic inflammation.

    Time frame: Baseline (Week 0), Pre-Intervention (Week 12), Post-Intervention (Week 24), and Follow-up (Week 36)

  2. Change in Plasma Interleukin-6 (IL-6) Levels (pg/mL)

    IL-6 will be quantified using proteomic analysis (Olink platform). Mean change across timepoints will be used to assess inflammatory signaling.

    Time frame: Baseline (Week 0), Week 12, Week 24, Week 36

  3. Change in Plasma Proteomic Profile (Normalized Protein Expression Units)

    Quantitative proteomic profiling will be performed using the Olink Reveal platform. A composite score derived from selected proteins related to immune function, oxidative stress, and metabolism will be analyzed using normalized protein expression (NPX) values.

    Time frame: Baseline (Week 0), Week 12, Week 24, Week 36

  4. Change in Circulating Metabolomic Biomarkers (Concentration Units, mmol/L or µmol/L)

    Metabolomic profiling will be conducted using nuclear magnetic resonance (NMR) spectroscopy, quantifying biomarkers related to lipid metabolism, amino acids, and energy pathways. Mean changes in selected metabolites will be analyzed.

    Time frame: Baseline, Week 12, Week 24, Week 36

  5. Change in Perceived Stress Score (Perceived Stress Scale, PSS-10)

    Perceived stress will be assessed using the 10-item Perceived Stress Scale (PSS-10), a validated measure of perceived stress over the past month (score range: 0-40; higher scores indicate greater perceived stress).

    Time frame: Baseline (Week 0), Week 12, Week 24, Week 36

  6. Change in Daily Emotional Wellbeing Score (App-Based Self-Assessment)

    Emotional wellbeing will be assessed using a daily app-based self-report measure (mood and emotional state), collected using a visual Likert or pictorial (Self-Assessment Manikin-style) scale. Scores will be averaged over 7-day periods prior to each assessment timepoint (range: 0-4; higher scores indicate worse wellbeing).

    Time frame: Weeks 0, 12, 24, and 36 (7-day averages prior to each assessment)

07

Study locations

1 of 1 sites recruiting
  • Yas Clinic
    Abu Dhabi, United Arab Emirates
    Recruiting
08

References and documents

Publications

  • Simpson-Yap S, Nag N, Probst Y, Reece JC, Jelinek GA, Neate S. Prospective associations of better quality of the diet with improved quality of life over 7.5 years in people with multiple sclerosis. Mult Scler Relat Disord. 2022 Apr;60:103710. doi: 10.1016/j.msard.2022.103710. Epub 2022 Feb 21. PubMed 35219239 ↗
  • Nauta IM, Loughlin KNM, Gravesteijn AS, van Wegen J, Hofman RP, Wilmsen N, Coles E, van Kempen ZLE, Killestein J, van Oosten BW, Strijbis EMM, Uitdehaag BMJ, de Jong BA. A multi-domain lifestyle intervention in multiple sclerosis: a longitudinal observational study. J Neurol. 2025 Jun 24;272(7):476. doi: 10.1007/s00415-025-13196-9. PubMed 40553232 ↗
  • Sanchez JMS, DePaula-Silva AB, Libbey JE, Fujinami RS. Role of diet in regulating the gut microbiota and multiple sclerosis. Clin Immunol. 2022 Feb;235:108379. doi: 10.1016/j.clim.2020.108379. Epub 2020 Mar 7. No abstract available. PubMed 32156562 ↗
  • Mannino A, Lithander FE, Dunlop E, Hoare S, Shivappa N, Daly A, Phillips M, Pereira G, Sherriff J, Lucas RM, Ponsonby AL, Hebert JR, van der Mei I, Black LJ; Ausimmune Investigator Group. A proinflammatory diet is associated with an increased likelihood of first clinical diagnosis of central nervous system demyelination in women. Mult Scler Relat Disord. 2022 Jan;57:103428. doi: 10.1016/j.msard.2021.103428. Epub 2021 Nov 24. PubMed 34856497 ↗
  • Coe S, Tektonidis TG, Coverdale C, Penny S, Collett J, Chu BTY, Izadi H, Middleton R, Dawes H. A cross sectional assessment of nutrient intake and the association of the inflammatory properties of nutrients and foods with symptom severity in a large cohort from the UK Multiple Sclerosis Registry. Nutr Res. 2021 Jan;85:31-39. doi: 10.1016/j.nutres.2020.11.006. Epub 2020 Nov 20. PubMed 33444968 ↗

Individual participant data

Plan to share: No — De-identified IPD may be shared upon reasonable request, subject to institutional approvals and data protection regulations. All shared data will be fully anonymized to protect participant confidentiality. Due to the sensitive nature of multi-omics and health-related data, access may be restricted and governed by data use agreements to ensure compliance with ethical and regulatory standards.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Nov 2027, 19 months after the start.

Of 79 non-industry interventional studies with no phase under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 47. This study's planned 19 months is below that.

Counting every sponsor, half of 81 studies reached it within 29 months; a quarter within 15 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2026
First posted
May 15, 2026
StartActual
Apr 15, 2026
Primary completionEst.
Nov 15, 2027
CompletionEst.
Nov 15, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 16, 2026
Sites
Yas Clinic is now Recruiting
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Not yet recruiting→Recruiting
    Yas Clinic is now Recruiting
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07589062
Lead sponsor
New York University Abu Dhabi
Responsible party
Sponsor
First posted
May 15, 2026
Start date
Apr 15, 2026
Primary completion
Nov 15, 2027 (estimated)
Completion
Nov 15, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Natascha Enriquez, MSc
Contact
natasha.enriquez@nyu.edu
+971501821961
Youssef Idaghdour, Professor
Contact
yi3@nyu.edu
+971561845775
Youssef Idaghdour, Professor
principal investigator · New York University Abu Dhabi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion